Bladder Cancer Therapeutics Market Size, Share, Growth Report 2032

Bladder Cancer Therapeutics Market

Bladder Cancer Therapeutics Market: by Cancer Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, and Other Rare Types), and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025

Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-4966 Published Date: Nov-2019 Status : Published
Market Size in 2018 Market Forecast in 2025 CAGR (in %) Base Year
USD 3,611.6 million USD 4,816.9 million 4.2% 2018

Bladder Cancer Therapeutics Market

Bladder Cancer Therapeutics Market: Industry Perspective

According to the report, the global demand for bladder cancer therapeutics market was valued at approximately USD 3,611.6 million in 2018 and is likely to generate revenue of around USD 4,816.9 million by end of 2025, growing at a CAGR of around 4.2% between 2019 and 2025.

Global Bladder Cancer Therapeutics Market SizeRequest Free Sample

Bladder Cancer Therapeutics Market: Overview

The report covers forecasts and analyses for the global bladder cancer therapeutics market. The study provides historic data from 2016 to 2018 along with estimates from 2019 to 2025 based on revenue (USD Million). In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. Macro-economic indicators such as healthcare industry outlook, healthcare spending, research funding, GDP along with company websites, company annual reports, white papers, financial reports, and other sources have also been considered to arrive at the indicated market numbers.

Bladder cancer is caused due to rapid and uncontrolled growth of abnormal cells in the urinary bladder. These cancerous cells spread through the lining of the muscular wall of the bladder. More cancer cells develop to form a tumor that can also spread into other parts of the body. A number of therapies have evolved to treat bladder cancers, which has boosted the demand for bladder cancer therapeutics in the market.

Bladder Cancer Therapeutics Market: Segmentation

The study provides a decisive view of the bladder cancer therapeutics market by segmenting the market based on cancer type, treatment, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on cancer type the market is segmented into transitional cell bladder cancer, superficial bladder cancer, invasive bladder cancer, squamous cell bladder cancer, and other rare types. The transitional cell bladder segment held the major share of the market in 2018.

On the basis of treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, and others. The chemotherapy segment held the major share of the market in 2018 due to the availability of a large number of chemotherapy drugs in the market. Regional segmentation includes the current and forecast demand for the Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. North America and Europe held the major share of the market in 2018. Innovative healthcare solutions, advanced infrastructure, rising geriatric population base, are likely to boost the growth of the market in these regions. Besides, rising awareness about all types of cancers and the availability of various treatment options, government initiatives, and increasing health care services are also further impeding the market growth.

The study also includes drivers and restraints for bladder cancer therapeutics along with the impact they have on the demand over the forecast period. Besides, the report includes the study of opportunities and trends available in the bladder cancer therapeutics market on a global level. Bladder cancer is among the 9th most frequently diagnosed cancer. As per the stats provided by the American Cancer Society in 2017, which estimated about 17,000 deaths due to bladder cancer and around 80,000 new bladder cancer cases.  Bladder cancer is among the 4th most common cancer in men, but less common in women, and accounts for about 5-6% of all new cancers in the U.S. Geriatric population is more prone to bladder cancer. In the U.K., bladder cancer is among the 7th most common types of cancer, and around 10,000 people are diagnosed with this cancer every year.

Bladder Cancer Therapeutics Market: Report Scope

Report Attributes Report Details
Report Name Bladder Cancer Therapeutics Market Research Report
Market Size in 2018 USD 3,611.6 million
Market Forecast in 2025 USD 4,816.9 million
Growth Rate CAGR of 4.2%
Number of Pages 214
Key Companies Covered Novartis AG, Sanofi S.A., Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Celgene Corporation, and Merck & Co.
Segments Covered By Cancer Type, By Treatment, And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2017
Historical Year 2014 to 2016
Forecast Year 2019 - 2025
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Bladder Cancer Therapeutics Market: Key Players

The report also provides a company market share analysis in order to give a broader view of the key players in the market. Industry insights and information is delivered in the required format. ZMR develops a list of industry players (manufacturers), distributors, retailers, and industry experts. Some of the key players included in the market are:

  • Novartis AG
  • Sanofi S.A.
  • Pfizer Inc.
  • Eli Lilly and Company
  • AstraZeneca plc
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Celgene Corporation
  • Merck & Co.

This report segments the bladder cancer therapeutics market as follows:

Global Bladder Cancer Therapeutics Market: Cancer Type Segment Analysis

  • Transitional Cell Bladder Cancer
  • Superficial Bladder Cancer
  • Invasive Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Rare Types

Global Bladder Cancer Therapeutics Market: Treatment Segment Analysis

Global Bladder Cancer Therapeutics Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Bladder cancer is caused due to rapid and uncontrolled growth of abnormal cells in the urinary bladder. These cancerous cells spread through the lining of the muscular wall of the bladder. 
 

The global bladder cancer therapeutics market  accounted for USD 3,611.6 million in 2018 and is expected to reach  USD 4,816.9 million by 2025.
 

The CAGR value of the bladder cancer therapeutics market is expected to be around 4.2% during 2019-2025.
 

North America and Europe held the major share of the market in 2018. Innovative healthcare solutions, advanced infrastructure, rising geriatric population base, are likely to boost the growth of the market in these regions.

Some key players of the global bladder cancer therapeutics market are Novartis AG, Sanofi S.A., Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Celgene Corporation, and Merck & Co.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed